ArticlePloS one2013
Multiple independent introductions of HIV-1 CRF01_AE identified in China: what are the implications for prevention?
Article in PloS one, 2013. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 11 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
11 citing papers in PubMed.
- Global spread and evolutionary trajectories of HIV-1 CRF01_AE: Insights from phylogenetic analysis.PloS one · 2026Article
- Independent epidemic patterns of HIV-1 CRF01_AE lineages driven by mobile population in Shenzhen, an immigrant city of China.Virus evolution · 2021Article
- Cross-Continental Dispersal of Major HIV-1 CRF01_AE Clusters in China.Frontiers in microbiology · 2020Article
- HIV-1 genotype diversity and distribution characteristics among heterosexually transmitted population in Jiangsu province, China.Virology journal · 2019Article
- Article
- Phylodynamics of major CRF01_AE epidemic clusters circulating in mainland of China.Scientific reports · 2017Article
- Tracing the epidemic history of HIV-1 CRF01_AE clusters using near-complete genome sequences.Scientific reports · 2017Article
- Article
- A Polyglot Approach to Bioinformatics Data Integration: A Phylogenetic Analysis of HIV-1.Evolutionary bioinformatics online · 2016Article
- Identification of a novel HIV-1 intra-circulating recombinant form 01_AE in China: a descendant of the previously identified CRF01_AE transmission clusters 1 and 6.Science China. Life sciences · 2015Article
- Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
4 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
backgroundHIV-1 CRF01_AE accounts for an important fraction of HIV infections in Asia including China, but little is known about the phylogenetic and evolutionary history of this CRF (circulating recombinant form). In the current study, we collected a large number of 1,957 CRF01_AE gag p17 sequences with known sampling year (1990-2010) from 5 global regions representing 15 countries to better understand the phylogenetic relationships and epidemic history of CRF01_AE strains in China. METHODOLOGY/PRINCIPAL
findingsCRF01_AE gag p17 sequences were retrieved from public databases to explore phylogenetic relationships and phylogeographic dynamics of CRF01_AE in Asia by using maximum-likelihood phylogenetics and Bayesian coalescent-based analyses. We found close phylogenetic relationships between sequences from Thailand, Vietnam and China. Moreover, at least 5 independent introductions and 5 independent autochthonous clades of CRF01_AE, which descended from Thailand or Vietnam were identified in China from 1991 through 2003. CONCLUSION/SIGNIFICANCE: The current study not only defines the migration of CRF01_AE clades to/in Asia, but also demonstrates the criticalness of identifying the circulating strains in the population for the development of vaccine and microbicides.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.